BR112021014897A2 - Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica - Google Patents

Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica Download PDF

Info

Publication number
BR112021014897A2
BR112021014897A2 BR112021014897-3A BR112021014897A BR112021014897A2 BR 112021014897 A2 BR112021014897 A2 BR 112021014897A2 BR 112021014897 A BR112021014897 A BR 112021014897A BR 112021014897 A2 BR112021014897 A2 BR 112021014897A2
Authority
BR
Brazil
Prior art keywords
compound
formula
use according
group
radical
Prior art date
Application number
BR112021014897-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Mohamad Firas BASSISSI
Carolina Salcedo Roca
Joan Perelló Bestard
Miquel David Ferrer Reynés
María Del Mar Pérez Ferrer
Original Assignee
Sanifit Therapeutics, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics, S.A. filed Critical Sanifit Therapeutics, S.A.
Publication of BR112021014897A2 publication Critical patent/BR112021014897A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021014897-3A 2019-01-30 2020-01-30 Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica BR112021014897A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382061.0 2019-01-30
EP19382061 2019-01-30
US201962913259P 2019-10-10 2019-10-10
US62/913,259 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
BR112021014897A2 true BR112021014897A2 (pt) 2021-09-28

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021014897-3A BR112021014897A2 (pt) 2019-01-30 2020-01-30 Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica

Country Status (11)

Country Link
US (2) US20220000889A1 (https=)
EP (1) EP3917535A1 (https=)
JP (2) JP2022521119A (https=)
KR (1) KR20210148078A (https=)
CN (1) CN113365636A (https=)
AU (1) AU2020213713B2 (https=)
BR (1) BR112021014897A2 (https=)
CA (1) CA3130735A1 (https=)
IL (1) IL285084A (https=)
MX (1) MX2021008966A (https=)
WO (1) WO2020157362A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
MX2023005931A (es) * 2020-11-20 2023-08-03 Vifor Int Ag Analogos de hexakisfosfato de inositol para el tratamiento de enfermedades renales asociadas con la calcificacion.
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO2001013933A2 (en) * 1999-08-25 2001-03-01 Gmp Companies, Inc. Agents for the enhanced oxygen delivery in mammals
AU7995600A (en) * 1999-10-05 2001-05-10 Theramed, Inc. Compositions and methods for the incorporation of chemical substances into cells
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020142995A1 (en) * 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
CN105949234B (zh) 2011-09-29 2018-07-10 苏黎世联邦理工学院 用于治疗艰难梭菌感染的药物化合物
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
EA037572B1 (ru) * 2015-12-11 2021-04-15 Этх Цюрих Производные инозитола для применения в патологической кристаллизации
DK3386994T3 (da) 2015-12-11 2020-01-13 Eth Zuerich 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion

Also Published As

Publication number Publication date
CN113365636A (zh) 2021-09-07
AU2020213713B2 (en) 2025-08-21
US20220000889A1 (en) 2022-01-06
CA3130735A1 (en) 2020-08-06
MX2021008966A (es) 2021-11-04
US20230248749A1 (en) 2023-08-10
EP3917535A1 (en) 2021-12-08
AU2020213713A1 (en) 2021-07-22
IL285084A (en) 2021-09-30
JP2022521119A (ja) 2022-04-06
JP2024175025A (ja) 2024-12-17
KR20210148078A (ko) 2021-12-07
WO2020157362A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
US20230248749A1 (en) Inositol phosphate compounds for use in increasing tissular perfusion
JP2016512821A (ja) ヘモグロビンの修飾のための組成物及び方法
US6610702B2 (en) Ammonium salts of inositol hexaphosphate, and uses thereof
EP3124023B1 (en) Durable preparation of an injectable of melatonin exhibiting long-term stability
US20220339171A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascula calcification
TWI564291B (zh) 一氧化氮生成調節劑
RU2270679C2 (ru) Лекарственное средство для лечения гипертензии
JPH1087483A (ja) 神経系および心循環系に対する酸化ストレスにより惹起する疾患の予防および治療のためのｌ−カルニチンまたはその誘導体と抗酸化剤の使用
BR112017012396B1 (pt) Combinação farmacêutica que compreende um agonista seletivo do receptor s1p1
LU85639A1 (fr) Compositions pharmaceutiques et procede de preparation de compositions de phosphatidylserine utilisables au traitement de desordres du systeme nerveux central sans exercer d'effets sur la coagulation du sang
JP2010510973A (ja) 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用
CA3224544A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
BR112020012004A2 (pt) composição medicinal para prevenir ou tratar hiperparatireoidismo secundário em diálise de manutenção, e, uso de uma composição medicinal campo da invenção
TW201717959A (zh) 用於對金屬卟啉進行微粒遞送之調配物及用途
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
US20220023240A1 (en) Compound for treating cancer and diabetes
Hu et al. Pyruvate as a novel carrier of hydroxyethyl starch 130/0.4 may protect kidney in rats subjected to severe burns
KR102917330B1 (ko) 이소성 석회화의 치료를 위한 이노시톨 포스페이트
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
HK40066584A (zh) 用於治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物
WO1999004783A1 (en) Composition for protection from damage by ischemia
BR112021006004B1 (pt) Uso de inositol hexafosfato
WO2008013822A2 (en) Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use
CN102764250A (zh) 一种由牛磺酸和银杏内酯a组成的组合物及其用途
Natarajan Liposomal formulations of alkyl nitrites and their efficacy in nitrosylation of blood

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIFOR (INTERNATIONAL) LTD. (CH)